Biotech Values

[DewDiligence]

AMGN cuts Repatha’s US list price 60%—to $5,850/yr—inline with actual post-rebate price:

https://finance.yahoo.com/news/amgen-cuts-price-cholesterol-drug-202946728.html

For patients getting Repatha through Medicare Part D (or Medicare Advantage with a Part-D component), a fixed copay amount will replace the standard coinsurance calculated as a percentage of the list price, saving these patients a considerable sum—see slide #8 below.


CC slides:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NzAwODczfENoaWxkSUQ9NDEyNDY0fFR5cGU9MQ==&t=1